SRR5088861
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- GLYCOLYSIS+0.300
- MTORC1_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PANCREAS_BETA_CELLS+0.300
- PROTEIN_SECRETION+0.300
- SPERMATOGENESIS+0.300
- FATTY_ACID_METABOLISM+0.200
- HYPOXIA+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- COMPLEMENT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- TGF_BETA_SIGNALING-0.400
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- KRAS_SIGNALING_UP-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900595 | — | — | 0.856 |
| 2 | ERR2208893 | — | — | 0.831 |
| 3 | s0112311 | — | — | 0.817 |
| 4 | TCGA-B6-A1KF-01A-11R-A13Q-07 | — | E | 0.816 |
| 5 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.814 |
| 6 | TCGA-OR-A5LE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.810 |
| 7 | s0095123 | — | — | 0.809 |
| 8 | SRR4296106 | — | cohortSQ1 | 0.808 |
| 9 | 034df4c4-52bd-4025-aee4-ad630d0d00af | — | — | 0.806 |
| 10 | b09c5d28-8a02-4343-b678-07cbf351ed44 | — | — | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |